• Paclitaxel (Taxol): Optimizing Cancer Research Protocols

  2026-05-29

  Paclitaxel (Taxol) is a linchpin compound in cancer research, powering cell cycle and apoptosis studies across in vitro and in vivo systems. This article delivers actionable, evidence-based workflows and troubleshooting strategies to maximize reproducibility and insight when using APExBIO’s Paclitaxel in cutting-edge oncology research.

• Pol II Degradation Triggers Cell Death Beyond Transcription

  2026-05-29

  This study reveals that targeted degradation of RNA polymerase II (Pol II) activates cell death independently of global transcriptional shutdown. These findings advance our understanding of regulated cell death mechanisms in DNA damage response research, with implications for cancer biology and therapeutic targeting.

• p-Cresyl Sulfate for Endothelial Dysfunction and Calcificati

  2026-05-28

  p-Cresyl sulfate from APExBIO enables robust modeling of uremic toxin-induced endothelial dysfunction and vascular calcification, critical for cardiovascular and renal disease research. This guide translates cutting-edge findings into practical workflows, troubleshooting, and advanced applications for translational scientists.

• Muscle-Derived BDNF Orchestrates Postsynaptic Assembly at NM

  2026-05-28

  This study uncovers how muscle-generated BDNF, regulated through activity- and calcium-dependent mechanisms, spatially directs the initial formation of postsynaptic acetylcholine receptor clusters at neuromuscular junctions (NMJs). The findings elucidate the subcellular trafficking, localized release, and proteolytic processing of BDNF, advancing our understanding of early NMJ development and providing a mechanistic framework for future research on synaptic assembly.

• Machine Learning Predicts Lipid Nanoparticles for mRNA Vacci

  2026-05-27

  This study pioneers a machine learning approach for predicting optimal lipid nanoparticle (LNP) formulations in mRNA vaccine development, achieving high predictive accuracy for in vivo efficacy. The findings accelerate rational ionizable lipid selection—including SM-102—reducing experimental workload and guiding future mRNA delivery system design.

• Vascular Responsiveness in Septic Shock: VNERi as a Prognost

  2026-05-27

  Goury et al. introduce the VNERi index—diastolic arterial pressure adjusted for norepinephrine dose and heart rate—as a superior bedside marker of vascular responsiveness in early septic shock. Their findings suggest VNERi outperforms traditional hemodynamic indices in predicting clinical outcomes, informing therapeutic strategies in critical care.

• OLIG2 Post-Translational Modifications Drive Glioma Invasion

  2026-05-26

  This study uncovers how phosphorylation status of the CNS-specific transcription factor OLIG2 determines the balance between proliferation and invasion in glioblastoma, acting through regulation of the TGF-β2 signaling axis. These mechanistic insights identify new molecular targets for therapeutic modulation of glioma invasiveness.

• ALDOB K87 Lactylation Drives Mitochondrial Fission in PH

  2026-05-26

  Yi et al. identify ALDOB K87 lactylation as a key driver of mitochondrial fission and metabolic reprogramming in pulmonary hypertension. Their mechanistic study reveals a lactate–ALDOB–DRP1 axis that promotes pathological vascular remodeling, offering new insight into PH progression and potential therapeutic targets.

• HyperScript First-Strand cDNA Synthesis Kit: Advancing RNA A

  2026-05-25

  The HyperScript First-Strand cDNA Synthesis Kit streamlines high-fidelity cDNA synthesis from challenging RNA samples, including low-abundance and highly structured transcripts. Its robust enzyme engineering and flexible primer options enable sensitive, reproducible results in PCR and qPCR workflows for cutting-edge transcriptomics.

• MK-0812: Deconstructing CCR2-Driven Monocyte Recruitment in

  2026-05-25

  Explore MK-0812 as a precise tool for dissecting CCR2-dependent monocyte trafficking in MASH research. This article offers a deeper, systems-level analysis of MK-0812’s applications and mechanistic impact, uniquely bridging advanced immunometabolic models with recent gut–liver axis discoveries.

• Cy7 NHS Ester: Protocols for Near-Infrared Biomolecule Label

  2026-05-24

  Cy7 NHS ester addresses the need for highly water-soluble, sulfonated near-infrared fluorescent labeling of proteins and peptides, especially in applications sensitive to organic solvents or protein denaturation. It is best suited for in vitro and in vivo imaging workflows requiring minimized fluorescence quenching and robust signal in aqueous environments. This reagent is not appropriate where target biomolecules lack accessible amino groups or where long-term solution storage is required.

• Doxorubicin Hydrochloride in Cancer Research: Protocols & Pi

  2026-05-23

  Leveraging Doxorubicin hydrochloride (Adriamycin HCl) from APExBIO enables robust modeling of cancer cytotoxicity and cardiotoxicity in both in vitro and in vivo studies. This article details experimental workflows, troubleshooting strategies, and innovative insights inspired by recent advances in rRNA-driven nucleolar architecture and DNA damage response.

• Ionomycin Calcium Salt: Next-Gen Insights in Calcium Signali

  2026-05-22

  Explore how ionomycin calcium salt empowers translational researchers to dissect the calcium signaling pathway, with mechanistic context from recent advances in metastasis biology and apoptosis induction. Learn how this calcium ionophore, through strategic experimental deployment, is reshaping the competitive landscape of cancer research and biomolecular interrogation.

• ML-7 Hydrochloride in Disease Modeling: Mechanistic and Tran

  2026-05-22

  Explore how ML-7 hydrochloride, a potent myosin light chain kinase inhibitor, powers advanced research in cardiovascular, oncology, and vascular models. This article delivers mechanistic depth and practical guidance for assay design, distinguishing itself with a focused analysis of recent translational findings.

• 7-Ethyl-10-hydroxycamptothecin: Precision Tools for Colon Ca

  2026-05-21

  7-Ethyl-10-hydroxycamptothecin empowers researchers to dissect S-phase and G2 arrest and apoptosis in metastatic colon cancer models, leveraging dual inhibition of DNA topoisomerase I and FUBP1-mediated transcription. This guide details robust workflows, protocol optimizations, and troubleshooting for reproducible, high-impact experimental results.

460 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page